Cellectar BioSciences Inc. has presented its latest corporate presentation, highlighting the development of Phospholipid Drug Conjugates (PDCs). The company has validated its PDC platform, which shows promise in delivering various oncology therapeutic modalities, including radioisotopes. Notably, their advanced Phospholipid Radioconjugate (PRC), iopofosine I-131, has exceeded efficacy endpoints in a phase 2 study for Waldenstrom's macroglobulinemia $(WM)$. The company has finalized its confirmatory study design and regulatory pathway for potential FDA accelerated approval. Additionally, Cellectar has ongoing studies for other assets, such as CLR 125 and CLR 225, targeting triple-negative breast cancer and pancreatic cancer, respectively. You can access the full presentation through the link below.